You are here
A ‘top 20’ ranking of countries with the largest Global Fund 2020-2022 allocations for the three diseases
Mozambique, India, and Nigeria received the largest allocations for HIV, TB and malaria
Sir Elton John joins Replenishment appeal, Japan’s Replenishment pledge, #FillUpTheFund campaign launch, Botswana’s landmark ruling on LGBT rights, South Africa’s ‘human rights’ plan for TB and HIV
Sir Elton John joins President Emmanuel Macron in calling for a $14-billion Global Fund Replenishment
Largest single award was for a South African TB/HIV grant
Domestic commitments for the programs included in the country grants amounted to $7.5 billion
Multi-country grant for Southern Africa receives $12 million
On 22 February 2019, the Global Fund Board approved one multi-country grant, one matching funds request and one set of interventions on the Unfunded Quality Demand (UQD) Register –– worth a total of $16.0 million. The Board was acting on the recommendations of the Technical Review Panel (TRP) and the Grant Approvals Committee (GAC). This was the 17th batch of approvals from the 2017–2019 allocations.
South Africa confronts HIV prevention challenge for adolescent girls and young women with new Global Fund grant
This will be the Global Fund’s largest investment by far in AGYW programming
South Africa, home to the largest national HIV epidemic globally, is getting ready to begin implementation of a new Global Fund grant for the period 1 April 2019 to 31 March 2022 in the amount of $353.3 million. The funding request was submitted during Window 6 (on 6 August 2018) and was reviewed by the Technical Review Panel (TRP) in September 2018.
The TRP recommended South Africa’s funding request.
Another $66 million was approved for interventions on the UQD Register
On 31 January 2019, the Global Fund Board approved three country grants worth $13.4 million. It also approved two multicountry grants valued at $22.5 million. The Board was acting on the recommendations of the Technical Review Panel (TRP) and the Grant Approvals Committee (GAC). See Tables 1 and 2 for listings of the country and multi-country grants.
Medical supplies authority obtains competitive prices that are often lower than international averages
The Kenya Medical Supplies Authority (KEMSA) successfully procures and distributes government, Global Fund, and other donor-funded commodities. Prices obtained by KEMSA are competitive compared to prices obtained by the Global Fund’s Pooled Procurement Mechanism (PPM), stock-outs of health commodities occur rarely, if ever, commodities are delivered in a timely fashion, and inventory is properly managed at all stages of the supply chain.
OIG investigation reveals deficiencies in Global Fund processes for procurement of HIV rapid test kits in eight countries
Country teams have already taken corrective action
A proactive investigation undertaken by the Office of the Inspector General (OIG) has identified some deficiencies in the Global Fund’s processes for procuring HIV rapid diagnostic test (RDT) kits. A report on the investigation was released on 31 May 2018.
Outcomes-based financing approach could reduce the risks associated with innovation
Part 2 of a 3-part series
In the beginning, there was performance-based funding. It was the outcomes-based mechanism of choice for the Global Fund and forms the foundation on which the Global Fund’s grant architecture was built. The idea was simple. Release funding in tranches, whereby recipients were required to reach specific targets before the rest of the grant would be disbursed.
State-of-the-art fixed dose combination regimen will cost $75 per patient per year
In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.